(7E,10E,13E,16E)-N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (7E,10E,13E,16E)-N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide
• 化学式: C₂₄H₄₁NO₂
• 分子量: 375.6
• InChiKey: FMVHVRYFQIXOAF-CGRWFSSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  27
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
  申请人：BODYBIO INC

  公开号：US10052339B2

  公开（公告）日：2018-08-21

  This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.

  本发明涉及含有平衡磷脂酰胆碱组合物和一种或多种大麻素、其天然或合成衍生物或其盐的组合物，以及含有此类组合物的试剂盒和使用此类组合物治疗患有脂肪酸失衡及相关疾病或紊乱的受试者的方法。本发明还涉及此类组合疗法在人体中的协同作用。
• Methods and compositions for treating diseases related to imbalance of essential fatty acids
  申请人：BODYBIO INC.

  公开号：US11129842B2

  公开（公告）日：2021-09-28

  This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.

  本发明涉及含有平衡磷脂酰胆碱组合物和一种或多种大麻素、其天然或合成衍生物或其盐的组合物，以及含有此类组合物的试剂盒和使用此类组合物治疗患有脂肪酸失衡及相关疾病或紊乱的受试者的方法。本发明还涉及此类组合疗法在人体中的协同作用。
• USE OF TOPICAL FORMULATIONS OF CANNABINOIDS IN THE TREATMENT OF EPIDERMOLYSIS BULLOSA AND RELATED CONNECTIVE TISSUE DISORDERS
  申请人：Inmed Pharmaceuticals Inc.

  公开号：EP3452036A1

  公开（公告）日：2019-03-13
• METABOLIC ENGINEERING OF E. COLI FOR THE BIOSYNTHESIS OF CANNABINOID PRODUCTS
  申请人：Inmed Pharmaceuticals Inc.

  公开号：EP3679146A1

  公开（公告）日：2020-07-15
• TOPICAL FORMULATIONS OF CANNABINOIDS AND USE THEREOF IN THE TREATMENT OF PAIN
  申请人：Inmed Pharmaceuticals Inc.

  公开号：EP3684353A1

  公开（公告）日：2020-07-29